Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Quotient Limited (QTNT)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
0.2448-0.0142 (-5.48%)
At close: 04:00PM EDT
0.2575 +0.01 (+5.19%)
After hours: 07:32PM EDT
Advertisement

Quotient Limited

Business Park Terre Bonne
Route de Crassier 13
Eysins 1262
Switzerland
11 41 22 716 9800
https://www.quotientbd.com

Sector(s)Healthcare
IndustryMedical Devices
Full Time Employees436

Key Executives

NameTitlePayExercisedYear Born
Mr. Manuel O. MendezCEO & Director10.22MN/A1968
Mr. Ali KiboroChief Financial Officer798.9kN/A1975
Mr. Mohammad El KhouryChief Commercial Officer544.83kN/A1960
Ms. Vittoria BonassoHead of Fin., Group Controller & Principal Accounting OfficerN/AN/A1976
Dr. Michael HausmannChief Technology OfficerN/AN/AN/A
Dr. Christine GinocchioChief Scientific & Medical OfficerN/AN/AN/A
Mr. Christian AlbrichChief People OfficerN/AN/A1964
Mr. Esteban UriarteChief Manufacturing Operations OfficerN/AN/AN/A
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, commercializes, and sells products for the global transfusion diagnostics market in the United States, France, Japan, and internationally. The company is developing MosaiQ, a proprietary technology platform, which provides tests for immunohematology, serological disease screening, and molecular disease screening. Its conventional reagent products for blood grouping include antisera products that are used to identify blood group antigens; reagent red blood cells, which enable the identification of blood group antibodies; whole blood control products for use as daily quality assurance tests; and ancillary products that are used to support blood grouping. The company also offers MosaiQ SDS Microarray that is designed as a serological disease screening microarray comprised assays to detect cytomegalovirus and Syphilis; MosaiQ MDS Microarray that is designed as a molecular disease screening microarray test for donor red cells or source plasma; MosaiQ IH Microarray as a blood grouping microarray; MosaiQ Autoimmune Microarray; MosaiQ COVID-19; and MosaiQ IH3 Microarray. It sells its products to hospitals, donor collection agencies, independent testing laboratories, original equipment manufacturers, and blood banking operation and other diagnostics companies. Quotient Limited was founded in 2007 and is headquartered in Eysins, Switzerland.

Corporate Governance

Quotient Limited’s ISS Governance QualityScore as of July 31, 2022 is 6. The pillar scores are Audit: 10; Board: 4; Shareholder Rights: 3; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement